Relamorelin, a ghrelin agonist, led to both symptomatic improvement and acceleration of gastric emptying in three studies, but the subsequent phase 3 trial was terminated prematurely, apparently for commercial reasons [79]
But Dr Georgia Rigas, former Chair of RACGP Specific Interests Obesity Management, said the research should be interpreted with caution, adding that prescribers can help to reduce negative outcomes by providing patients with a list of symptoms to look out for and how to respond if they develop
Medved I, Brown MJ, Bjorksten AR: N-acetylcysteine infusion alters blood redox status but not time to fatigue during intense exercise in humans
The April 30, 2026 FDA proposal would further close the 503B bulks pathway permanently
Wright et al
Here's a look at the IV menu clients